Loading page…

THE PEPTIDE RESEARCH REFERENCE

A clearer view of peptide research.

Explore compounds, source material, and research tools in one organized reference.

Explore the directory Open calculator

Research & education. Never medical advice.

Independent research reference Sources kept in context Practical calculation tools

THE DIRECTORY

Explore peptides45

A growing collection of compounds, blends, and source material.

Adamax: proposed cognitive-support pathway. Modified Semax with an adamantane group and structural caps; intended to resist breakdown and improve brain entry; proposed BDNF activity associated with neuron growth and neuroplasticity. Reported effects: focus and clarity, motivation, memory support. Proposed mechanisms and anecdotal benefits, not established in human clinical trials. Source overview: Klearmind.

About this imageAdamax: proposed cognitive-support pathway. Modified Semax with an adamantane group and structural caps; intended to resist breakdown and improve brain entry; proposed BDNF activity associated with neuron growth and neuroplasticity. Reported effects: focus and clarity, motivation, memory support. Proposed mechanisms and anecdotal benefits, not established in human clinical trials. Source overview: Klearmind.Open research profile COMPOUND

Adamax

AOD-9604. Proposed fat-metabolism pathway. GH-derived fragment: Modified peptide: AOD-9604. Lipid metabolism: Fat-breakdown research: Fat-storage signaling. Proposed outcome: Mobilize stored fat: Body-composition support. Reported benefits: Fat mobilization, Less fat storage, Body composition. Animal mechanism; human weight-loss benefit was not demonstrated.

COMPOUND

AOD-9604

BPC-157. Proposed tissue-repair pathway. Research peptide: BPC-157: Tissue-repair studies. Repair signaling: Blood-vessel research: Cell-migration pathways. Proposed outcome: Connective-tissue repair: Gut-lining support. Reported benefits: Tendon recovery, Gut support, Muscle recovery. Preclinical pathway; reported human benefits remain unverified.

COMPOUND

BPC-157

WOLVERINE. Proposed combined recovery pathway. BPC-157: Repair-signaling research: Gut and tendon models. TB-500: Thymosin-related claims: Cell-movement rationale. Blend rationale: Complementary pathways: Combined repair support. Proposed benefits: Tissue repair, Recovery, Mobility. Proposed blend effects; combination benefits remain unverified.

BLENDWOLVERINE

BPC-157 / TB-500 (WOLVERINE)

Cagrilintide. Amylin signaling and appetite. Amylin analogue: Long-acting peptide: Cagrilintide. Satiety signals: Activates amylin receptors: Signals meal fullness. Eating behavior: Earlier fullness: Reduced food intake. Studied effects: Appetite control, Reduced food intake, Weight management. Human trial findings; monotherapy and combination results differ.

COMPOUND

Cagrilintide

CJC-1295 with DAC. Prolonged growth-hormone signaling. DAC modification: Albumin-binding design: Longer circulation. Pituitary signal: GHRH receptor activity: GH and IGF-1 response. Proposed outcome: Sustained hormone signal: Repair and metabolism. Reported benefits: Recovery, Sleep quality, Body composition. Hormone effects are studied; broader benefit claims remain unverified.

About this imageCJC-1295 with DAC. Prolonged growth-hormone signaling. DAC modification: Albumin-binding design: Longer circulation. Pituitary signal: GHRH receptor activity: GH and IGF-1 response. Proposed outcome: Sustained hormone signal: Repair and metabolism. Reported benefits: Recovery, Sleep quality, Body composition. Hormone effects are studied; broader benefit claims remain unverified.Open research profile COMPOUND

CJC-1295 w/ DAC

CJC / IPA. Proposed dual GH-release pathway. CJC component: GHRH-related signal: Exact CJC form matters. Ipamorelin component: Ghrelin-receptor signal: GH-release rationale. Combined rationale: Two signaling inputs: Pituitary GH release. Proposed benefits: Recovery, Sleep quality, Body composition. Proposed blend effects; combination benefits remain unverified.

About this imageCJC / IPA. Proposed dual GH-release pathway. CJC component: GHRH-related signal: Exact CJC form matters. Ipamorelin component: Ghrelin-receptor signal: GH-release rationale. Combined rationale: Two signaling inputs: Pituitary GH release. Proposed benefits: Recovery, Sleep quality, Body composition. Proposed blend effects; combination benefits remain unverified.Open research profile BLEND

CJC/IPA

DSIP. Proposed sleep-support pathway. Sleep-related peptide: Delta sleep-inducing peptide: DSIP. Proposed signaling: Sleep and stress pathways: Mechanism still debated. Reported outcome: Deeper sleep: Overnight recovery. Reported benefits: Sleep quality, Stress support, Recovery. Proposed pathway and reports; human sleep trials are limited.

COMPOUND

DSIP

GHK-Cu. Proposed skin-and-repair pathway. Copper peptide: GHK-Cu complex: Copper-binding tripeptide. Repair signaling: Collagen-related activity: Extracellular matrix. Proposed outcome: Skin remodeling: Wound-support rationale. Reported benefits: Skin quality, Wound support, Hair support. Topical and preclinical evidence; systemic benefit claims are unverified.

About this imageGHK-Cu. Proposed skin-and-repair pathway. Copper peptide: GHK-Cu complex: Copper-binding tripeptide. Repair signaling: Collagen-related activity: Extracellular matrix. Proposed outcome: Skin remodeling: Wound-support rationale. Reported benefits: Skin quality, Wound support, Hair support. Topical and preclinical evidence; systemic benefit claims are unverified.Open research profile COMPOUND

GHK-Cu

GLOW. Proposed skin-and-recovery blend. GHK-Cu: Copper-peptide signaling: Skin-matrix research. BPC-157 + TB-500: Tissue-repair rationale: Complementary claims. Blend rationale: Skin and tissue support: Combined recovery claims. Proposed benefits: Skin quality, Tissue recovery, Repair support. Proposed blend effects; combination benefits remain unverified.

BLENDGLOW

GHK-Cu / BPC-157 / TB-500 (GLOW)

KLOW. Proposed repair-and-inflammation blend. GLOW components: GHK-Cu + BPC-157: Plus TB-500. Added KPV: Inflammation research: Cell-signaling rationale. Blend rationale: Repair plus inflammation: Combined support claims. Proposed benefits: Skin support, Tissue recovery, Inflammation support. Proposed blend effects; combination benefits remain unverified.

BLENDKLOW

GHK-Cu / BPC-157 / TB-500 / KPV (KLOW)

Glutathione. Cellular antioxidant pathway. Natural tripeptide: Made in the body: Glutathione. Antioxidant cycle: Balances oxidation: Supports redox reactions. Proposed outcome: Cellular protection: Stress-defense support. Biological roles and claims: Antioxidant defense, Cellular support, Recovery. Normal biology is established; added wellness benefits vary by context.

About this imageGlutathione. Cellular antioxidant pathway. Natural tripeptide: Made in the body: Glutathione. Antioxidant cycle: Balances oxidation: Supports redox reactions. Proposed outcome: Cellular protection: Stress-defense support. Biological roles and claims: Antioxidant defense, Cellular support, Recovery. Normal biology is established; added wellness benefits vary by context.Open research profile COMPOUND

Glutathione

Ipamorelin. Proposed recovery-and-sleep pathway. Research peptide: Ipamorelin: Ghrelin-receptor agonist. Pituitary signal: Stimulates GH release: Downstream growth signals. Proposed outcome: Repair and metabolism: Sleep-support rationale. Reported benefits: Recovery, Sleep quality, Body composition. Hormone effects are studied; broader benefit claims remain unverified.

About this imageIpamorelin. Proposed recovery-and-sleep pathway. Research peptide: Ipamorelin: Ghrelin-receptor agonist. Pituitary signal: Stimulates GH release: Downstream growth signals. Proposed outcome: Repair and metabolism: Sleep-support rationale. Reported benefits: Recovery, Sleep quality, Body composition. Hormone effects are studied; broader benefit claims remain unverified.Open research profile COMPOUND

Ipamorelin

Kisspeptin. Reproductive signaling pathway. Kisspeptin signal: Forms include 10 and 54: Reproductive peptide. Upstream trigger: Activates kisspeptin receptor: Promotes GnRH release. Hormone cascade: LH and FSH signaling: Gonadal response. Studied and reported effects: Fertility support, Hormone signaling, Sexual function. Fertility evidence is formulation-specific; broader claims remain provisional.

About this imageKisspeptin. Reproductive signaling pathway. Kisspeptin signal: Forms include 10 and 54: Reproductive peptide. Upstream trigger: Activates kisspeptin receptor: Promotes GnRH release. Hormone cascade: LH and FSH signaling: Gonadal response. Studied and reported effects: Fertility support, Hormone signaling, Sexual function. Fertility evidence is formulation-specific; broader claims remain provisional.Open research profile COMPOUND

Kisspeptin

KPV. Proposed inflammation-support pathway. Tripeptide: Lysine-proline-valine: KPV. Cellular signaling: PepT1 uptake research: NF-kappaB / MAPK pathways. Proposed outcome: Calmer inflammation: Gut and skin support. Reported benefits: Gut comfort, Skin support, Inflammation support. Preclinical pathway; reported human benefits remain unverified.

COMPOUND

KPV

MOTS-c. Proposed metabolic-resilience pathway. Mitochondrial peptide: MOTS-c: Cellular stress signal. Metabolic signaling: AMPK activation research: Folate and purine pathways. Proposed outcome: Glucose-use support: Exercise-adaptation rationale. Reported benefits: Metabolic support, Exercise support, Healthy aging. Preclinical pathway; reported human benefits remain unverified.

About this imageMOTS-c. Proposed metabolic-resilience pathway. Mitochondrial peptide: MOTS-c: Cellular stress signal. Metabolic signaling: AMPK activation research: Folate and purine pathways. Proposed outcome: Glucose-use support: Exercise-adaptation rationale. Reported benefits: Metabolic support, Exercise support, Healthy aging. Preclinical pathway; reported human benefits remain unverified.Open research profile COMPOUND

MOTS-C

MT-1. Melanin-production pathway. Afamelanotide: Common MT-1 meaning: Melanocortin analogue. MC1 receptor: Signals pigment cells: Increases eumelanin. Pigment response: More skin pigmentation: Light-tolerance benefit in EPP. Biological and clinical effects: Pigmentation, EPP light tolerance, Skin pigment response. EPP evidence applies to the prescribed implant, not unverified tanning products.

About this imageMT-1. Melanin-production pathway. Afamelanotide: Common MT-1 meaning: Melanocortin analogue. MC1 receptor: Signals pigment cells: Increases eumelanin. Pigment response: More skin pigmentation: Light-tolerance benefit in EPP. Biological and clinical effects: Pigmentation, EPP light tolerance, Skin pigment response. EPP evidence applies to the prescribed implant, not unverified tanning products.Open research profile COMPOUND

MT-1

MT-2. Melanotan II signaling pathway. Cyclic peptide: MT-2 means Melanotan II: Melanocortin analogue. Receptor activity: Skin and brain signaling: Multiple melanocortin receptors. Reported outcome: More pigmentation: Appetite and libido effects. Reported benefits: Pigmentation, Libido effects, Appetite effects. Early studies and reports; cosmetic-use safety is unestablished.

About this imageMT-2. Melanotan II signaling pathway. Cyclic peptide: MT-2 means Melanotan II: Melanocortin analogue. Receptor activity: Skin and brain signaling: Multiple melanocortin receptors. Reported outcome: More pigmentation: Appetite and libido effects. Reported benefits: Pigmentation, Libido effects, Appetite effects. Early studies and reports; cosmetic-use safety is unestablished.Open research profile COMPOUND

MT-2

NAD+. Cellular energy-and-repair pathway. Cellular coenzyme: NAD+: Present in every cell. Electron transfer: Redox reactions: Energy metabolism. Cellular functions: Mitochondrial activity: Repair-enzyme substrate. Biological roles and claims: Cellular energy, DNA repair biology, Metabolic support. Cellular roles are established; infusion wellness benefits remain unverified.

About this imageNAD+. Cellular energy-and-repair pathway. Cellular coenzyme: NAD+: Present in every cell. Electron transfer: Redox reactions: Energy metabolism. Cellular functions: Mitochondrial activity: Repair-enzyme substrate. Biological roles and claims: Cellular energy, DNA repair biology, Metabolic support. Cellular roles are established; infusion wellness benefits remain unverified.Open research profile COMPOUND

NAD+

Oxytocin. Hormone and social-signaling pathways. Peptide hormone: Oxytocin: Brain and body signaling. Receptor activity: Uterine contractions: Social-circuit research. Reported brain effects: Bonding and intimacy: Stress-response claims. Reported benefits: Bonding, Intimacy, Stress support. Obstetric effects are established; behavioral benefits are context-dependent.

About this imageOxytocin. Hormone and social-signaling pathways. Peptide hormone: Oxytocin: Brain and body signaling. Receptor activity: Uterine contractions: Social-circuit research. Reported brain effects: Bonding and intimacy: Stress-response claims. Reported benefits: Bonding, Intimacy, Stress support. Obstetric effects are established; behavioral benefits are context-dependent.Open research profile COMPOUND

Oxytocin

PT-141. Brain-based sexual-desire pathway. Bremelanotide: Also called PT-141: Melanocortin agonist. Central signaling: Activates melanocortin receptors: Sexual-response pathways. Clinical context: Desire and distress: Specific HSDD population. Studied effects: Sexual desire, Reduced distress, Central signaling. Clinical evidence applies to VYLEESI in eligible premenopausal women.

About this imagePT-141. Brain-based sexual-desire pathway. Bremelanotide: Also called PT-141: Melanocortin agonist. Central signaling: Activates melanocortin receptors: Sexual-response pathways. Clinical context: Desire and distress: Specific HSDD population. Studied effects: Sexual desire, Reduced distress, Central signaling. Clinical evidence applies to VYLEESI in eligible premenopausal women.Open research profile COMPOUND

PT-141

RT (RO-R3). Retatrutide pathway under a catalog alias. Catalog alias: RT / RO-R3: Site alias for retatrutide. Triple signaling: GIP + GLP-1 + glucagon: Appetite and metabolism. Research outcomes: Weight reduction: Metabolic-marker changes. Studied effects of retatrutide: Appetite control, Weight reduction, Metabolic effects. Retatrutide trial evidence; an alias does not verify a product.

About this imageRT (RO-R3). Retatrutide pathway under a catalog alias. Catalog alias: RT / RO-R3: Site alias for retatrutide. Triple signaling: GIP + GLP-1 + glucagon: Appetite and metabolism. Research outcomes: Weight reduction: Metabolic-marker changes. Studied effects of retatrutide: Appetite control, Weight reduction, Metabolic effects. Retatrutide trial evidence; an alias does not verify a product.Open research profile COMPOUND

RT (RO-R3)

Selank. Proposed calm-and-focus pathway. Synthetic peptide: Selank: Tuftsin-related analogue. Proposed brain signaling: GABA-related research: Neuropeptide modulation. Reported outcome: Less anxious tension: Clearer attention. Reported benefits: Calm, Stress resilience, Focus. Limited human research and proposed mechanisms; broader benefits are unverified.

COMPOUND

Selank

Semax. Proposed neurotrophin-support pathway. ACTH-related analogue: Semax: Synthetic peptide. Proposed brain pathway: BDNF / trkB signaling: Neuroplasticity research. Reported outcome: Sharper attention: Learning and mood support. Reported benefits: Focus, Memory support, Motivation. Neurotrophin findings are largely preclinical; cognitive claims remain provisional.

About this imageSemax. Proposed neurotrophin-support pathway. ACTH-related analogue: Semax: Synthetic peptide. Proposed brain pathway: BDNF / trkB signaling: Neuroplasticity research. Reported outcome: Sharper attention: Learning and mood support. Reported benefits: Focus, Memory support, Motivation. Neurotrophin findings are largely preclinical; cognitive claims remain provisional.Open research profile COMPOUND

Semax

Sermorelin. Proposed natural-GH support pathway. GHRH fragment: Sermorelin: GRF(1-29) amide. Pituitary signal: Stimulates GH release: Downstream IGF-1. Proposed outcome: Repair and metabolism: Sleep-support rationale. Reported benefits: Recovery, Sleep quality, Body composition. Historical clinical hormone uses; adult wellness claims remain unverified.

COMPOUND

Sermorelin

SS-31. Mitochondrial membrane-support pathway. Elamipretide: Research name SS-31: Mitochondria-targeting peptide. Cardiolipin binding: Inner mitochondrial membrane: Membrane-function rationale. Proposed cell effects: Energy-production support: Oxidative-stress research. Studied and proposed effects: Cellular energy, Muscle function, Stress resilience. Specific Barth-syndrome approval; general wellness claims remain unverified.

About this imageSS-31. Mitochondrial membrane-support pathway. Elamipretide: Research name SS-31: Mitochondria-targeting peptide. Cardiolipin binding: Inner mitochondrial membrane: Membrane-function rationale. Proposed cell effects: Energy-production support: Oxidative-stress research. Studied and proposed effects: Cellular energy, Muscle function, Stress resilience. Specific Barth-syndrome approval; general wellness claims remain unverified.Open research profile COMPOUND

SS-31

T-60. Vendor-interpreted tirzepatide pathway. Reported identity: T60 used for tirzepatide: Vendor-based interpretation. If tirzepatide: GIP + GLP-1 agonism: Brain and pancreas signaling. Expected pathway: Appetite regulation: Glucose-dependent insulin. Effects if identity matches: Appetite control, Glucose control, Weight management. Conditional on tirzepatide identity; this catalog match is unverified.

About this imageT-60. Vendor-interpreted tirzepatide pathway. Reported identity: T60 used for tirzepatide: Vendor-based interpretation. If tirzepatide: GIP + GLP-1 agonism: Brain and pancreas signaling. Expected pathway: Appetite regulation: Glucose-dependent insulin. Effects if identity matches: Appetite control, Glucose control, Weight management. Conditional on tirzepatide identity; this catalog match is unverified.Open research profile COMPOUND

T-60

Tesamorelin. Growth signaling and visceral-fat pathway. GHRH analogue: Tesamorelin: Peptide medicine. Pituitary pathway: Stimulates GH release: Increases IGF-1. Clinical target: Excess visceral fat: HIV-associated lipodystrophy. Studied effects: Visceral-fat reduction, GH signaling, Body composition. Evidence applies to HIV-associated lipodystrophy, not general weight loss.

About this imageTesamorelin. Growth signaling and visceral-fat pathway. GHRH analogue: Tesamorelin: Peptide medicine. Pituitary pathway: Stimulates GH release: Increases IGF-1. Clinical target: Excess visceral fat: HIV-associated lipodystrophy. Studied effects: Visceral-fat reduction, GH signaling, Body composition. Evidence applies to HIV-associated lipodystrophy, not general weight loss.Open research profile COMPOUND

Tesamorelin

Thymosin Alpha 1. Proposed immune-support pathway. Thymalfasin: Thymosin Alpha 1: Immunomodulatory peptide. Immune modulation: T-cell-related signaling: Innate and adaptive responses. Proposed outcome: Immune-response support: Infection-response research. Reported benefits: Immune support, Infection response, Healthy-aging claims. Disease-specific studies have mixed results; general immune boosting is unverified.

About this imageThymosin Alpha 1. Proposed immune-support pathway. Thymalfasin: Thymosin Alpha 1: Immunomodulatory peptide. Immune modulation: T-cell-related signaling: Innate and adaptive responses. Proposed outcome: Immune-response support: Infection-response research. Reported benefits: Immune support, Infection response, Healthy-aging claims. Disease-specific studies have mixed results; general immune boosting is unverified.Open research profile COMPOUND

Thymosin Alpha 1

5-Amino-1MQ. Proposed metabolic-support pathway. Small molecule: 5-Amino-1MQ: NNMT inhibitor. Enzyme target: Reduces NNMT activity: Changes cell metabolism. Proposed outcome: Adipose metabolism: Fat-loss rationale. Reported benefits: Fat loss, Metabolic support, Cellular energy. Preclinical pathway; reported human benefits remain unverified.

COMPOUND

5-Amino-1MQ

CJC-1295. Growth-hormone signaling pathway. GHRH analogue: CJC-1295 label: Formulation matters. Pituitary signal: Stimulates GH release: Downstream IGF-1. Proposed outcome: Repair and metabolism: Body-composition support. Reported benefits: Recovery, Sleep quality, Body composition. Hormone effects are studied; broader benefit claims remain unverified.

COMPOUND

CJC-1295

Epitalon. Proposed cellular-aging pathway. Tetrapeptide: Epitalon: Cellular-aging research. Cellular target: Telomerase research: Telomere maintenance. Proposed outcome: Cellular resilience: Healthy-aging rationale. Reported benefits: Healthy aging, Cell maintenance, Sleep quality. Cell findings and reported benefits; human longevity is unproven.

COMPOUND

Epitalon

GHRP-2. Ghrelin signaling and GH release. GH secretagogue: GHRP-2: Ghrelin-receptor agonist. Hormone response: Stimulates GH release: Appetite signaling. Proposed outcome: Repair and metabolism: Body-composition support. Reported benefits: Recovery, Muscle support, Appetite effects. Hormone effects are studied; broader benefit claims remain unverified.

COMPOUND

GHRP-2

GHRP-6. GH release and appetite signaling. Hexapeptide: GHRP-6: Ghrelin-receptor agonist. Hormone response: Stimulates GH release: Appetite stimulation. Proposed outcome: Nutrient intake: Recovery rationale. Reported benefits: Appetite, Muscle support, Recovery. Hormone effects are studied; broader benefit claims remain unverified.

COMPOUND

GHRP-6

Gonadorelin. Reproductive hormone pathway. Synthetic GnRH: Gonadorelin: Hypothalamic signal mimic. Pituitary response: Releases LH and FSH: Signals the gonads. Proposed outcome: Reproductive signaling: Hormone-support rationale. Reported benefits: Fertility support, Hormone signaling, Libido support. Diagnostic hormone effects are established; wellness claims are unverified.

About this imageGonadorelin. Reproductive hormone pathway. Synthetic GnRH: Gonadorelin: Hypothalamic signal mimic. Pituitary response: Releases LH and FSH: Signals the gonads. Proposed outcome: Reproductive signaling: Hormone-support rationale. Reported benefits: Fertility support, Hormone signaling, Libido support. Diagnostic hormone effects are established; wellness claims are unverified.Open research profile COMPOUND

Gonadorelin

HGH Fragment 176–191. Proposed lipid-metabolism pathway. GH fragment label: C-terminal peptide region: Exact sequence matters. Metabolic rationale: Fat-breakdown claims: Fat-storage research. Proposed outcome: Stored-fat mobilization: Body-composition support. Reported benefits: Fat mobilization, Less fat storage, Body composition. Related-fragment research and claims; human fat-loss efficacy is unverified.

About this imageHGH Fragment 176–191. Proposed lipid-metabolism pathway. GH fragment label: C-terminal peptide region: Exact sequence matters. Metabolic rationale: Fat-breakdown claims: Fat-storage research. Proposed outcome: Stored-fat mobilization: Body-composition support. Reported benefits: Fat mobilization, Less fat storage, Body composition. Related-fragment research and claims; human fat-loss efficacy is unverified.Open research profile COMPOUND

HGH Fragment 176-191

Hexarelin. GH release and repair rationale. GH secretagogue: Synthetic peptide: Ghrelin-receptor activity. Hormone response: Stimulates GH release: Other hormones affected. Proposed outcome: Muscle and tissue support: Recovery rationale. Reported benefits: Muscle support, Recovery, Body composition. Hormone effects are studied; broader benefit claims remain unverified.

About this imageHexarelin. GH release and repair rationale. GH secretagogue: Synthetic peptide: Ghrelin-receptor activity. Hormone response: Stimulates GH release: Other hormones affected. Proposed outcome: Muscle and tissue support: Recovery rationale. Reported benefits: Muscle support, Recovery, Body composition. Hormone effects are studied; broader benefit claims remain unverified.Open research profile COMPOUND

Hexarelin

IGF-1 LR3. Proposed growth-and-repair pathway. Modified IGF-I: IGF-1 LR3: Research analogue. Altered availability: Lower binding-protein affinity: IGF-related signaling. Proposed outcome: Cell-growth pathways: Muscle-repair rationale. Reported benefits: Muscle growth, Recovery, Nutrient use. Preclinical pathway; reported human benefits remain unverified.

COMPOUND

IGF-1 LR3

LL-37. Host-defense and repair pathway. Host-defense peptide: Human cathelicidin: LL-37. Biological targets: Microbial membranes: Immune-signaling pathways. Proposed outcome: Barrier defense: Wound-support rationale. Biological roles and claims: Microbial defense, Wound support, Barrier support. Biological and laboratory roles; systemic treatment claims are unverified.

About this imageLL-37. Host-defense and repair pathway. Host-defense peptide: Human cathelicidin: LL-37. Biological targets: Microbial membranes: Immune-signaling pathways. Proposed outcome: Barrier defense: Wound-support rationale. Biological roles and claims: Microbial defense, Wound support, Barrier support. Biological and laboratory roles; systemic treatment claims are unverified.Open research profile COMPOUND

LL-37

MK-677. Ghrelin-mimetic growth signaling. Ibutamoren: Small molecule: Also called MK-677. Hormone signal: Mimics ghrelin activity: Raises GH and IGF-1. Proposed outcome: Lean-tissue support: Sleep and recovery claims. Studied and reported effects: Lean mass, Sleep quality, Recovery. Hormone and lean-mass effects studied; strength gains were not demonstrated.

COMPOUND

MK-677

Melanotan II. Melanocortin signaling pathway. Cyclic analogue: Melanotan II: Also called MT-2. Receptor activity: Melanocortin signaling: Pigment and brain pathways. Reported outcome: More pigmentation: Appetite and libido effects. Reported benefits: Pigmentation, Libido effects, Appetite effects. Early studies and reports; cosmetic-use safety is unestablished.

About this imageMelanotan II. Melanocortin signaling pathway. Cyclic analogue: Melanotan II: Also called MT-2. Receptor activity: Melanocortin signaling: Pigment and brain pathways. Reported outcome: More pigmentation: Appetite and libido effects. Reported benefits: Pigmentation, Libido effects, Appetite effects. Early studies and reports; cosmetic-use safety is unestablished.Open research profile COMPOUND

Melanotan II

Retatrutide. Three-receptor weight-management pathway. Triple agonist: GIP + GLP-1 + glucagon: Investigational peptide. Combined signaling: Appetite regulation: Energy-metabolism pathways. Clinical outcomes: Lower body weight: Metabolic-marker research. Studied effects: Appetite control, Weight reduction, Metabolic effects. Clinical trial findings; research products are not validated medicines.

About this imageRetatrutide. Three-receptor weight-management pathway. Triple agonist: GIP + GLP-1 + glucagon: Investigational peptide. Combined signaling: Appetite regulation: Energy-metabolism pathways. Clinical outcomes: Lower body weight: Metabolic-marker research. Studied effects: Appetite control, Weight reduction, Metabolic effects. Clinical trial findings; research products are not validated medicines.Open research profile COMPOUND

Retatrutide

Semaglutide. GLP-1 appetite-and-glucose pathway. GLP-1 agonist: Semaglutide: Peptide medicine. Brain and pancreas: Appetite regulation: Glucose-dependent insulin. Clinical outcomes: Reduced food intake: Lower body weight. Studied effects: Appetite control, Glucose control, Weight management. Benefits depend on the prescribed product, indication and patient.

COMPOUND

Semaglutide

TB-500. Proposed tissue-recovery pathway. Thymosin-related label: TB-500: Exact peptide identity matters. Proposed repair biology: Actin-related pathways: Cell-migration rationale. Reported outcome: Soft-tissue recovery: Mobility support. Reported benefits: Tissue recovery, Wound support, Mobility. Claims extrapolate thymosin biology; TB-500 human benefits are unverified.

About this imageTB-500. Proposed tissue-recovery pathway. Thymosin-related label: TB-500: Exact peptide identity matters. Proposed repair biology: Actin-related pathways: Cell-migration rationale. Reported outcome: Soft-tissue recovery: Mobility support. Reported benefits: Tissue recovery, Wound support, Mobility. Claims extrapolate thymosin biology; TB-500 human benefits are unverified.Open research profile COMPOUND

TB-500

Tirzepatide. Dual-receptor appetite-and-glucose pathway. Dual agonist: Tirzepatide: GIP + GLP-1. Brain and pancreas: Appetite regulation: Glucose-dependent insulin. Clinical outcomes: Reduced food intake: Lower body weight. Studied effects: Appetite control, Glucose control, Weight management. Benefits depend on the prescribed product, indication and patient.

COMPOUND

Tirzepatide

Good research starts with context.

Source information is preserved as supplied. Missing details are marked clearly, and imported protocols are not clinical recommendations.